Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epix Pharmaceuticals has reported results from a phase IIa clinical trial of its agent EP-2104R, demonstrating that it was effective at detecting blood clots.
Subscribe to our email newsletter
The results of the phase IIa trial found that EP-2104R was able to detect blood clots not previously seen on magnetic resonance imaging (MRI). Blood clots are a major underlying cause of several diseases including deep vein thrombosis, pulmonary embolism, heart attack and stroke.
The data show EP-2104R was well-tolerated and able to detect or enhance clots on MRI images in all six of the body systems studied. In many cases existing modalities are not able to provide a definitive thrombus diagnosis and multiple tests must be conducted to reach a definitive diagnosis.
Epix Pharmaceuticals said it believed EP-2104R could potentially replace multiple tests resulting in significant cost savings.
“EP-2104R detected previously unseen pathologies in some patients in the trial and the results show that we may be able to utilize EP-2104R in contrast enhanced vascular imaging,” said Josef Vymazal, Hospital Na Holmolce, Czech Republic.